Nome Uses AI to Map Rare-Disease Treatments in 10 Minutes for 5,000 Genetic Cases
Updated
Updated · CNBC · Aug 18
Nome Uses AI to Map Rare-Disease Treatments in 10 Minutes for 5,000 Genetic Cases
2 articles · Updated · CNBC · Aug 18
Summary
Nome says its AI platform can analyze a patient’s genetic test and return a detailed treatment-options report in about 10 minutes, targeting rare-disease groups that often lack a development roadmap.
Across roughly 5,000 cases reviewed, the startup says it has found a programmable medicine or existing custom therapy match about 25% of the time and now produces 80 to 100 reports a month.
The company then makes money by helping families and advocacy groups design trials and manage drug-development logistics; it currently oversees a little more than 10 genetic-medicine programs.
For the DAND Alliance—formed by five mothers after diagnoses affecting only about 200 known patients worldwide—Nome delivered a 53-page plan covering research gaps, animal studies and trial design.
Founder Stevie Ringel, who has a rare retinal disorder affecting fewer than 200 patients globally, says AI could automate 60% to 80% of the process within one to two years and cut customized ASO costs from $1.2 million-$1.4 million by half.